|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
DOI no:
|
Science
272:1001-1004
(1996)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Structures of an MHC class II molecule with covalently bound single peptides.
|
|
D.H.Fremont,
W.A.Hendrickson,
P.Marrack,
J.Kappler.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
The high-resolution x-ray crystal structures of the murine major
histocompatibility complex (MHC) class II molecule, I-E(k), occupied by either
of two antigenic peptides were determined. They reveal the structural basis for
the I-E(k) peptide binding motif and suggest general principles for additional
alleles. A buried cluster of acidic amino acids in the binding groove predicted
to be conserved among all murine I-E and human DR MHC class II molecules
suggests how pH may influence MHC binding or exchange of peptides. These
structures also complement mutational studies on the importance of individual
peptide residues to T cell receptor recognition.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
|
| |
PubMed id
|
|
Reference
|
|
|
|
|
|
D.Cížková,
J.Gouy de Bellocq,
S.J.Baird,
J.Piálek,
and
J.Bryja
(2011).
Genetic structure and contrasting selection pattern at two major histocompatibility complex genes in wild house mouse populations.
|
| |
Heredity,
106,
727-740.
|
|
|
|
|
|
|
J.Huan,
R.Meza-Romero,
J.L.Mooney,
A.A.Vandenbark,
H.Offner,
and
G.G.Burrows
(2011).
Single-chain recombinant HLA-DQ2.5/peptide molecules block α2-gliadin-specific pathogenic CD4+ T-cell proliferation and attenuate production of inflammatory cytokines: a potential therapy for celiac disease.
|
| |
Mucosal Immunol,
4,
112-120.
|
|
|
|
|
|
|
Y.Yin,
Y.Li,
M.C.Kerzic,
R.Martin,
and
R.A.Mariuzza
(2011).
Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection.
|
| |
EMBO J,
30,
1137-1148.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
E.A.James,
A.K.Moustakas,
J.Bui,
G.K.Papadopoulos,
G.Bondinas,
J.H.Buckner,
and
W.W.Kwok
(2010).
HLA-DR1001 presents "altered-self" peptides derived from joint-associated proteins by accepting citrulline in three of its binding pockets.
|
| |
Arthritis Rheum,
62,
2909-2918.
|
|
|
|
|
|
|
J.J.Sabatino,
K.M.Rosenthal,
and
B.D.Evavold
(2010).
Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE.
|
| |
J Neuroimmune Pharmacol,
5,
176-188.
|
|
|
|
|
|
|
K.T.Ballingall,
and
R.Tassi
(2010).
Sequence-based genotyping of the sheep MHC class II DRB1 locus.
|
| |
Immunogenetics,
62,
31-39.
|
|
|
|
|
|
|
M.A.Patarroyo,
A.Bermúdez,
C.López,
G.Yepes,
and
M.E.Patarroyo
(2010).
3D analysis of the TCR/pMHCII complex formation in monkeys vaccinated with the first peptide inducing sterilizing immunity against human malaria.
|
| |
PLoS One,
5,
e9771.
|
|
|
|
|
|
|
M.Philip,
A.Schietinger,
and
H.Schreiber
(2010).
Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells.
|
| |
Immunology,
130,
494-503.
|
|
|
|
|
|
|
S.Sadegh-Nasseri,
S.Natarajan,
C.L.Chou,
I.Z.Hartman,
K.Narayan,
and
A.Kim
(2010).
Conformational heterogeneity of MHC class II induced upon binding to different peptides is a key regulator in antigen presentation and epitope selection.
|
| |
Immunol Res,
47,
56-64.
|
|
|
|
|
|
|
V.Cecconi,
M.Moro,
S.Del Mare,
J.Sidney,
A.Bachi,
R.Longhi,
A.Sette,
M.P.Protti,
P.Dellabona,
and
G.Casorati
(2010).
The CD4+ T-cell epitope-binding register is a critical parameter when generating functional HLA-DR tetramers with promiscuous peptides.
|
| |
Eur J Immunol,
40,
1603-1616.
|
|
|
|
|
|
|
R.Yaneva,
S.Springer,
and
M.Zacharias
(2009).
Flexibility of the MHC class II peptide binding cleft in the bound, partially filled, and empty states: A molecular dynamics simulation study.
|
| |
Biopolymers,
91,
14-27.
|
|
|
|
|
|
|
W.L.Lo,
N.J.Felix,
J.J.Walters,
H.Rohrs,
M.L.Gross,
and
P.M.Allen
(2009).
An endogenous peptide positively selects and augments the activation and survival of peripheral CD4+ T cells.
|
| |
Nat Immunol,
10,
1155-1161.
|
|
|
|
|
|
|
E.A.James,
A.K.Moustakas,
D.Berger,
L.Huston,
G.K.Papadopoulos,
and
W.W.Kwok
(2008).
Definition of the peptide binding motif within DRB1*1401 restricted epitopes by peptide competition and structural modeling.
|
| |
Mol Immunol,
45,
2651-2659.
|
|
|
|
|
|
|
K.T.Ballingall,
K.Fardoe,
and
D.J.McKeever
(2008).
Genomic organisation and allelic diversity within coding and non-coding regions of the Ovar-DRB1 locus.
|
| |
Immunogenetics,
60,
95.
|
|
|
|
|
|
|
R.A.Harris,
K.Sugimoto,
D.E.Kaplan,
F.Ikeda,
M.Kamoun,
and
K.M.Chang
(2008).
Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans.
|
| |
Hepatology,
48,
70-79.
|
|
|
|
|
|
|
S.Dai,
F.Crawford,
P.Marrack,
and
J.W.Kappler
(2008).
The structure of HLA-DR52c: comparison to other HLA-DRB3 alleles.
|
| |
Proc Natl Acad Sci U S A,
105,
11893-11897.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
G.P.Bondinas,
A.K.Moustakas,
and
G.K.Papadopoulos
(2007).
The spectrum of HLA-DQ and HLA-DR alleles, 2006: a listing correlating sequence and structure with function.
|
| |
Immunogenetics,
59,
539-553.
|
|
|
|
|
|
|
K.Choudhuri,
and
P.A.van der Merwe
(2007).
Molecular mechanisms involved in T cell receptor triggering.
|
| |
Semin Immunol,
19,
255-261.
|
|
|
|
|
|
|
K.Narayan,
C.L.Chou,
A.Kim,
I.Z.Hartman,
S.Dalai,
S.Khoruzhenko,
and
S.Sadegh-Nasseri
(2007).
HLA-DM targets the hydrogen bond between the histidine at position beta81 and peptide to dissociate HLA-DR-peptide complexes.
|
| |
Nat Immunol,
8,
92.
|
|
|
|
|
|
|
T.Saitoh,
M.Igura,
T.Obita,
T.Ose,
R.Kojima,
K.Maenaka,
T.Endo,
and
D.Kohda
(2007).
Tom20 recognizes mitochondrial presequences through dynamic equilibrium among multiple bound states.
|
| |
EMBO J,
26,
4777-4787.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
E.Y.Jones,
L.Fugger,
J.L.Strominger,
and
C.Siebold
(2006).
MHC class II proteins and disease: a structural perspective.
|
| |
Nat Rev Immunol,
6,
271-282.
|
|
|
|
|
|
|
F.Crawford,
K.R.Jordan,
B.Stadinski,
Y.Wang,
E.Huseby,
P.Marrack,
J.E.Slansky,
and
J.W.Kappler
(2006).
Use of baculovirus MHC/peptide display libraries to characterize T-cell receptor ligands.
|
| |
Immunol Rev,
210,
156-170.
|
|
|
|
|
|
|
H.Tsukamoto,
A.Irie,
Y.Z.Chen,
K.Takeshita,
J.R.Kim,
and
Y.Nishimura
(2006).
TCR ligand avidity determines the mode of B-Raf/Raf-1/ERK activation leading to the activation of human CD4+ T cell clone.
|
| |
Eur J Immunol,
36,
1926-1937.
|
|
|
|
|
|
|
M.E.Patarroyo,
G.Cifuentes,
and
J.Baquero
(2006).
Comparative molecular and three-dimensional analysis of the peptide-MHC II binding region in both human and Aotus MHC-DRB molecules confirms their usefulness in antimalarial vaccine development.
|
| |
Immunogenetics,
58,
598-606.
|
|
|
|
|
|
|
N.J.Felix,
and
P.M.Allen
(2006).
Learning from the lost: new insights into TCR specificity.
|
| |
Nat Immunol,
7,
1127-1128.
|
|
|
|
|
|
|
A.Bonehill,
C.Heirman,
and
K.Thielemans
(2005).
Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.
|
| |
J Gene Med,
7,
686-695.
|
|
|
|
|
|
|
C.J.Roy,
K.L.Warfield,
B.C.Welcher,
R.F.Gonzales,
T.Larsen,
J.Hanson,
C.S.David,
T.Krakauer,
and
S.Bavari
(2005).
Human leukocyte antigen-DQ8 transgenic mice: a model to examine the toxicity of aerosolized staphylococcal enterotoxin B.
|
| |
Infect Immun,
73,
2452-2460.
|
|
|
|
|
|
|
H.Duyar,
J.Dengjel,
K.L.de Graaf,
K.H.Wiesmüller,
S.Stevanović,
and
R.Weissert
(2005).
Peptide motif for the rat MHC class II molecule RT1.Da: similarities to the multiple sclerosis-associated HLA-DRB1*1501 molecule.
|
| |
Immunogenetics,
57,
69-76.
|
|
|
|
|
|
|
J.D.Hayball,
and
R.A.Lake
(2005).
The immune function of MHC class II molecules mutated in the putative superdimer interface.
|
| |
Mol Cell Biochem,
273,
1-9.
|
|
|
|
|
|
|
K.Csencsits,
S.C.Wood,
G.Lu,
J.C.Magee,
E.J.Eichwald,
C.H.Chang,
and
D.K.Bishop
(2005).
Graft rejection mediated by CD4+ T cells via indirect recognition of alloantigen is associated with a dominant Th2 response.
|
| |
Eur J Immunol,
35,
843-851.
|
|
|
|
|
|
|
K.Oved,
A.Lev,
R.Noy,
D.Segal,
and
Y.Reiter
(2005).
Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes.
|
| |
Cancer Immunol Immunother,
54,
867-879.
|
|
|
|
|
|
|
M.Amicosante,
F.Berretta,
M.Rossman,
R.H.Butler,
P.Rogliani,
E.van den Berg-Loonen,
and
C.Saltini
(2005).
Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlubeta69.
|
| |
Respir Res,
6,
94.
|
|
|
|
|
|
|
M.Krogsgaard,
Q.J.Li,
C.Sumen,
J.B.Huppa,
M.Huse,
and
M.M.Davis
(2005).
Agonist/endogenous peptide-MHC heterodimers drive T cell activation and sensitivity.
|
| |
Nature,
434,
238-243.
|
|
|
|
|
|
|
N.A.Williamson,
and
A.W.Purcell
(2005).
Use of proteomics to define targets of T-cell immunity.
|
| |
Expert Rev Proteomics,
2,
367-380.
|
|
|
|
|
|
|
T.Elliott,
and
A.Williams
(2005).
The optimization of peptide cargo bound to MHC class I molecules by the peptide-loading complex.
|
| |
Immunol Rev,
207,
89-99.
|
|
|
|
|
|
|
Y.J.Cheng,
Q.Zhou,
and
Z.G.Li
(2005).
The inhibitory effect of altered collagen II peptide on HLA-DRB1-restricted T-cell activation.
|
| |
Scand J Immunol,
61,
260-265.
|
|
|
|
|
|
|
K.M.Williams,
and
E.C.Bigley
(2004).
Identification of an I-Ed-restricted T-cell epitope of Escherichia coli outer membrane protein F.
|
| |
Infect Immun,
72,
3907-3913.
|
|
|
|
|
|
|
R.Williams,
T.Schlüter,
M.S.Roberts,
P.Knauth,
R.Bohnensack,
and
D.F.Cutler
(2004).
Sorting nexin 17 accelerates internalization yet retards degradation of P-selectin.
|
| |
Mol Biol Cell,
15,
3095-3105.
|
|
|
|
|
|
|
T.C.Chen,
H.Waldmann,
and
P.J.Fairchild
(2004).
Induction of dominant transplantation tolerance by an altered peptide ligand of the male antigen Dby.
|
| |
J Clin Invest,
113,
1754-1762.
|
|
|
|
|
|
|
A.Trautmann,
and
C.Randriamampita
(2003).
Initiation of TCR signalling revisited.
|
| |
Trends Immunol,
24,
425-428.
|
|
|
|
|
|
|
A.W.Purcell,
W.Zeng,
N.A.Mifsud,
L.K.Ely,
W.A.Macdonald,
and
D.C.Jackson
(2003).
Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design.
|
| |
J Pept Sci,
9,
255-281.
|
|
|
|
|
|
|
S.B.Conant,
and
R.H.Swanborg
(2003).
MHC class II peptide flanking residues of exogenous antigens influence recognition by autoreactive T cells.
|
| |
Autoimmun Rev,
2,
8.
|
|
|
|
|
|
|
B.J.McFarland,
and
C.Beeson
(2002).
Binding interactions between peptides and proteins of the class II major histocompatibility complex.
|
| |
Med Res Rev,
22,
168-203.
|
|
|
|
|
|
|
C.A.Daubenberger,
B.Nickel,
C.Ciatto,
M.G.Grütter,
F.Pöltl-Frank,
L.Rossi,
U.Siegler,
J.Robinson,
O.Kashala,
M.E.Patarroyo,
and
G.Pluschke
(2002).
Amino acid dimorphism and parasite immune evasion: cellular immune responses to a promiscuous epitope of Plasmodium falciparum merozoite surface protein 1 displaying dimorphic amino acid polymorphism are highly constrained.
|
| |
Eur J Immunol,
32,
3667-3677.
|
|
|
|
|
|
|
D.H.Fremont,
S.Dai,
H.Chiang,
F.Crawford,
P.Marrack,
and
J.Kappler
(2002).
Structural basis of cytochrome c presentation by IE(k).
|
| |
J Exp Med,
195,
1043-1052.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
J.Hennecke,
and
D.C.Wiley
(2002).
Structure of a complex of the human alpha/beta T cell receptor (TCR) HA1.7, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4 (DRA*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity.
|
| |
J Exp Med,
195,
571-581.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
L.K.McNeil,
and
B.D.Evavold
(2002).
Dissociation of peripheral T cell responses from thymocyte negative selection by weak agonists supports a spare receptor model of T cell activation.
|
| |
Proc Natl Acad Sci U S A,
99,
4520-4525.
|
|
|
|
|
|
|
R.König
(2002).
Interactions between MHC molecules and co-receptors of the TCR.
|
| |
Curr Opin Immunol,
14,
75-83.
|
|
|
|
|
|
|
X.Liu,
S.Dai,
F.Crawford,
R.Fruge,
P.Marrack,
and
J.Kappler
(2002).
Alternate interactions define the binding of peptides to the MHC molecule IA(b).
|
| |
Proc Natl Acad Sci U S A,
99,
8820-8825.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
Z.Pu,
J.A.Carrero,
and
E.R.Unanue
(2002).
Distinct recognition by two subsets of T cells of an MHC class II-peptide complex.
|
| |
Proc Natl Acad Sci U S A,
99,
8844-8849.
|
|
|
|
|
|
|
B.J.McFarland,
J.F.Katz,
C.Beeson,
and
A.J.Sant
(2001).
Energetic asymmetry among hydrogen bonds in MHC class II*peptide complexes.
|
| |
Proc Natl Acad Sci U S A,
98,
9231-9236.
|
|
|
|
|
|
|
C.Viret,
X.He,
and
C.A.Janeway
(2001).
Paradoxical intrathymic positive selection in mice with only a covalently presented agonist peptide.
|
| |
Proc Natl Acad Sci U S A,
98,
9243-9248.
|
|
|
|
|
|
|
K.M.Haan,
A.Aiyar,
and
R.Longnecker
(2001).
Establishment of latent Epstein-Barr virus infection and stable episomal maintenance in murine B-cell lines.
|
| |
J Virol,
75,
3016-3020.
|
|
|
|
|
|
|
M.Kalbus,
B.T.Fleckenstein,
M.Offenhäusser,
M.Blüggel,
A.Melms,
H.E.Meyer,
H.G.Rammensee,
R.Martin,
G.Jung,
and
N.Sommer
(2001).
Ligand motif of the autoimmune disease-associated mouse MHC class II molecule H2-A(s).
|
| |
Eur J Immunol,
31,
551-562.
|
|
|
|
|
|
|
O.Schueler-Furman,
Y.Altuvia,
and
H.Margalit
(2001).
Examination of possible structural constraints of MHC-binding peptides by assessment of their native structure within their source proteins.
|
| |
Proteins,
45,
47-54.
|
|
|
|
|
|
|
T.Jensen,
M.Nielsen,
M.Gad,
P.Hansen,
S.Komba,
M.Meldal,
N.Ødum,
and
O.Werdelin
(2001).
Radically altered T cell receptor signaling in glycopeptide-specific T cell hybridoma induced by antigen with minimal differences in the glycan group.
|
| |
Eur J Immunol,
31,
3197-3206.
|
|
|
|
|
|
|
A.Simon,
Z.Dosztányi,
E.Rajnavölgyi,
and
I.Simon
(2000).
Function-related regulation of the stability of MHC proteins.
|
| |
Biophys J,
79,
2305-2313.
|
|
|
|
|
|
|
C.L.Chou,
and
S.Sadegh-Nasseri
(2000).
HLA-DM recognizes the flexible conformation of major histocompatibility complex class II.
|
| |
J Exp Med,
192,
1697-1706.
|
|
|
|
|
|
|
D.Scott,
C.Addey,
P.Ellis,
E.James,
M.J.Mitchell,
N.Saut,
S.Jurcevic,
and
E.Simpson
(2000).
Dendritic cells permit identification of genes encoding MHC class II-restricted epitopes of transplantation antigens.
|
| |
Immunity,
12,
711-720.
|
|
|
|
|
|
|
N.Abiru,
D.Wegmann,
E.Kawasaki,
P.Gottlieb,
E.Simone,
and
G.S.Eisenbarth
(2000).
Dual overlapping peptides recognized by insulin peptide B:9-23 T cell receptor AV13S3 T cell clones of the NOD mouse.
|
| |
J Autoimmun,
14,
231-237.
|
|
|
|
|
|
|
P.M.Kasson,
J.D.Rabinowitz,
L.Schmitt,
M.M.Davis,
and
H.M.McConnell
(2000).
Kinetics of peptide binding to the class II MHC protein I-Ek.
|
| |
Biochemistry,
39,
1048-1058.
|
|
|
|
|
|
|
R.R.Latek,
A.Suri,
S.J.Petzold,
C.A.Nelson,
O.Kanagawa,
E.R.Unanue,
and
D.H.Fremont
(2000).
Structural basis of peptide binding and presentation by the type I diabetes-associated MHC class II molecule of NOD mice.
|
| |
Immunity,
12,
699-710.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
R.V.Joshi,
J.A.Zarutskie,
and
L.J.Stern
(2000).
A three-step kinetic mechanism for peptide binding to MHC class II proteins.
|
| |
Biochemistry,
39,
3751-3762.
|
|
|
|
|
|
|
A.J.Sant,
C.Beeson,
B.McFarland,
J.Cao,
S.Ceman,
P.W.Bryant,
and
S.Wu
(1999).
Individual hydrogen bonds play a critical role in MHC class II: peptide interactions: implications for the dynamic aspects of class II trafficking and DM-mediated peptide exchange.
|
| |
Immunol Rev,
172,
239-253.
|
|
|
|
|
|
|
B.Fleckenstein,
G.Jung,
and
K.H.Wiesmüller
(1999).
Quantitative analysis of peptide-MHC class II interaction.
|
| |
Semin Immunol,
11,
405-416.
|
|
|
|
|
|
|
B.J.McFarland,
A.J.Sant,
T.P.Lybrand,
and
C.Beeson
(1999).
Ovalbumin(323-339) peptide binds to the major histocompatibility complex class II I-A(d) protein using two functionally distinct registers.
|
| |
Biochemistry,
38,
16663-16670.
|
|
|
|
|
|
|
C.B.Williams,
D.L.Engle,
G.J.Kersh,
J.Michael White,
and
P.M.Allen
(1999).
A kinetic threshold between negative and positive selection based on the longevity of the T cell receptor-ligand complex.
|
| |
J Exp Med,
189,
1531-1544.
|
|
|
|
|
|
|
C.I.Pearson,
A.M.Gautam,
I.C.Rulifson,
R.S.Liblau,
and
H.O.McDevitt
(1999).
A small number of residues in the class II molecule I-Au confer the ability to bind the myelin basic protein peptide Ac1-11.
|
| |
Proc Natl Acad Sci U S A,
96,
197-202.
|
|
|
|
|
|
|
E.Carrasco-Marin,
O.Kanagawa,
and
E.R.Unanue
(1999).
The lack of consensus for I-A(g7)-peptide binding motifs: is there a requirement for anchor amino acid side chains?
|
| |
Proc Natl Acad Sci U S A,
96,
8621-8626.
|
|
|
|
|
|
|
E.R.Unanue
(1999).
Rous-Whipple Award Lecture. Chemical features of peptide selection by the class II histocompatibility molecules.
|
| |
Am J Pathol,
154,
651-664.
|
|
|
|
|
|
|
J.A.Zarutskie,
A.K.Sato,
M.M.Rushe,
I.C.Chan,
A.Lomakin,
G.B.Benedek,
and
L.J.Stern
(1999).
A conformational change in the human major histocompatibility complex protein HLA-DR1 induced by peptide binding.
|
| |
Biochemistry,
38,
5878-5887.
|
|
|
|
|
|
|
J.F.Piskurich,
M.W.Linhoff,
Y.Wang,
and
J.P.Ting
(1999).
Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta.
|
| |
Mol Cell Biol,
19,
431-440.
|
|
|
|
|
|
|
J.van Bergen,
F.Ossendorp,
R.Jordens,
A.M.Mommaas,
J.W.Drijfhout,
and
F.Koning
(1999).
Get into the groove! Targeting antigens to MHC class II.
|
| |
Immunol Rev,
172,
87-96.
|
|
|
|
|
|
|
K.C.Garcia,
L.Teyton,
and
I.A.Wilson
(1999).
Structural basis of T cell recognition.
|
| |
Annu Rev Immunol,
17,
369-397.
|
|
|
|
|
|
|
K.Maenaka,
and
E.Y.Jones
(1999).
MHC superfamily structure and the immune system.
|
| |
Curr Opin Struct Biol,
9,
745-753.
|
|
|
|
|
|
|
N.M.Zirk,
S.F.Hashmi,
and
H.K.Ziegler
(1999).
The polysaccharide portion of lipopolysaccharide regulates antigen-specific T-cell activation via effects on macrophage-mediated antigen processing.
|
| |
Infect Immun,
67,
319-326.
|
|
|
|
|
|
|
R.N.Germain,
and
I.Stefanová
(1999).
The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation.
|
| |
Annu Rev Immunol,
17,
467-522.
|
|
|
|
|
|
|
R.R.Latek,
and
E.R.Unanue
(1999).
Mechanisms and consequences of peptide selection by the I-Ak class II molecule.
|
| |
Immunol Rev,
172,
209-228.
|
|
|
|
|
|
|
T.G.Anderson,
and
H.M.McConnell
(1999).
Interpretation of biphasic dissociation kinetics for isomeric class II major histocompatibility complex-peptide complexes
|
| |
Biophys J,
77,
2451-2461.
|
|
|
|
|
|
|
T.Jensen,
P.Hansen,
A.Faurskov Nielsen,
M.Meldal,
S.Komba,
and
O.Werdelin
(1999).
Shared structural motifs in TCR of glycopeptide-recognizing T cell hybridomas.
|
| |
Eur J Immunol,
29,
2759-2768.
|
|
|
|
|
|
|
C.A.Scott,
K.C.Garcia,
E.A.Stura,
P.A.Peterson,
I.A.Wilson,
and
L.Teyton
(1998).
Engineering protein for X-ray crystallography: the murine Major Histocompatibility Complex class II molecule I-Ad.
|
| |
Protein Sci,
7,
413-418.
|
|
|
|
|
|
|
C.A.Scott,
P.A.Peterson,
L.Teyton,
and
I.A.Wilson
(1998).
Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues.
|
| |
Immunity,
8,
319-329.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
C.Daniel,
S.Horvath,
and
P.M.Allen
(1998).
A basis for alloreactivity: MHC helical residues broaden peptide recognition by the TCR.
|
| |
Immunity,
8,
543-552.
|
|
|
|
|
|
|
C.Lee,
M.N.Liang,
K.M.Tate,
J.D.Rabinowitz,
C.Beeson,
P.P.Jones,
and
H.M.McConnell
(1998).
Evidence that the autoimmune antigen myelin basic protein (MBP) Ac1-9 binds towards one end of the major histocompatibility complex (MHC) cleft.
|
| |
J Exp Med,
187,
1505-1516.
|
|
|
|
|
|
|
D.Gerlier,
M.C.Trescol-Biémont,
L.Ettouati,
J.Paris,
and
C.Rabourdin-Combe
(1998).
An accessory peptide binding site with allosteric effect on the formation of peptide-MHC-II complexes?
|
| |
C R Acad Sci III,
321,
19-24.
|
|
|
|
|
|
|
D.H.Fremont,
D.Monnaie,
C.A.Nelson,
W.A.Hendrickson,
and
E.R.Unanue
(1998).
Crystal structure of I-Ak in complex with a dominant epitope of lysozyme.
|
| |
Immunity,
8,
305-317.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
D.H.Fremont,
F.Crawford,
P.Marrack,
W.A.Hendrickson,
and
J.Kappler
(1998).
Crystal structure of mouse H2-M.
|
| |
Immunity,
9,
385-393.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
G.J.Kersh,
E.N.Kersh,
D.H.Fremont,
and
P.M.Allen
(1998).
High- and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling.
|
| |
Immunity,
9,
817-826.
|
|
|
|
|
|
|
I.A.Wilson,
and
P.J.Bjorkman
(1998).
Unusual MHC-like molecules: CD1, Fc receptor, the hemochromatosis gene product, and viral homologs.
|
| |
Curr Opin Immunol,
10,
67-73.
|
|
|
|
|
|
|
J.Alexander,
J.Fikes,
S.Hoffman,
E.Franke,
J.Sacci,
E.Appella,
F.V.Chisari,
L.G.Guidotti,
R.W.Chesnut,
B.Livingston,
and
A.Sette
(1998).
The optimization of helper T lymphocyte (HTL) function in vaccine development.
|
| |
Immunol Res,
18,
79-92.
|
|
|
|
|
|
|
J.D.Rabinowitz,
M.Vrljic,
P.M.Kasson,
M.N.Liang,
R.Busch,
J.J.Boniface,
M.M.Davis,
and
H.M.McConnell
(1998).
Formation of a highly peptide-receptive state of class II MHC.
|
| |
Immunity,
9,
699-709.
|
|
|
|
|
|
|
J.J.Boniface,
J.D.Rabinowitz,
C.Wülfing,
J.Hampl,
Z.Reich,
J.D.Altman,
R.M.Kantor,
C.Beeson,
H.M.McConnell,
and
M.M.Davis
(1998).
Initiation of signal transduction through the T cell receptor requires the multivalent engagement of peptide/MHC ligands [corrected]
|
| |
Immunity,
9,
459-466.
|
|
|
|
|
|
|
K.J.Smith,
J.Pyrdol,
L.Gauthier,
D.C.Wiley,
and
K.W.Wucherpfennig
(1998).
Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein.
|
| |
J Exp Med,
188,
1511-1520.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
K.R.Ryan,
and
B.D.Evavold
(1998).
Persistence of peptide-induced CD4+ T cell anergy in vitro.
|
| |
J Exp Med,
187,
89-96.
|
|
|
|
|
|
|
L.Mosyak,
D.M.Zaller,
and
D.C.Wiley
(1998).
The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation.
|
| |
Immunity,
9,
377-383.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
L.Schmitt,
J.J.Boniface,
M.M.Davis,
and
H.M.McConnell
(1998).
Kinetic isomers of a class II MHC-peptide complex.
|
| |
Biochemistry,
37,
17371-17380.
|
|
|
|
|
|
|
M.Feng,
D.Chou,
Y.Liaw,
and
M.Lai
(1998).
Conserved T-cell receptor class II major histocompatibility complex contact detected in a T-lymphocyte population.
|
| |
Immunology,
95,
185-192.
|
|
|
|
|
|
|
P.J.Fairchild
(1998).
Presentation of antigenic peptides by products of the major histocompatibility complex.
|
| |
J Pept Sci,
4,
182-194.
|
|
|
|
|
|
|
P.Kjellén,
U.Brunsberg,
J.Broddefalk,
B.Hansen,
M.Vestberg,
I.Ivarsson,
A.Engström,
A.Svejgaard,
J.Kihlberg,
L.Fugger,
and
R.Holmdahl
(1998).
The structural basis of MHC control of collagen-induced arthritis; binding of the immunodominant type II collagen 256-270 glycopeptide to H-2Aq and H-2Ap molecules.
|
| |
Eur J Immunol,
28,
755-767.
|
|
|
|
|
|
|
T.Gyotoku,
Y.Fukui,
and
T.Sasazuki
(1998).
An endogenously processed self peptide and the corresponding exogenous peptide bound to the same MHC class II molecule could be distinct ligands for TCR with different kinetic stability.
|
| |
Eur J Immunol,
28,
4050-4061.
|
|
|
|
|
|
|
A.Dessen,
C.M.Lawrence,
S.Cupo,
D.M.Zaller,
and
D.C.Wiley
(1997).
X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II.
|
| |
Immunity,
7,
473-481.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
C.P.Liu,
D.Parker,
J.Kappler,
and
P.Marrack
(1997).
Selection of antigen-specific T cells by a single IEk peptide combination.
|
| |
J Exp Med,
186,
1441-1450.
|
|
|
|
|
|
|
E.Pareja,
R.Tobes,
J.Martín,
and
A.Nieto
(1997).
The tetramer model: a new view of class II MHC molecules in antigenic presentation to T cells.
|
| |
Tissue Antigens,
50,
421-428.
|
|
|
|
|
|
|
E.S.Ward,
and
A.Qadri
(1997).
Biophysical and structural studies of TCRs and ligands: implications for T cell signaling.
|
| |
Curr Opin Immunol,
9,
97.
|
|
|
|
|
|
|
E.Y.Jones
(1997).
MHC class I and class II structures.
|
| |
Curr Opin Immunol,
9,
75-79.
|
|
|
|
|
|
|
H.J.Ullrich,
K.Döring,
U.Grüneberg,
F.Jähnig,
J.Trowsdale,
and
S.M.van Ham
(1997).
Interaction between HLA-DM and HLA-DR involves regions that undergo conformational changes at lysosomal pH.
|
| |
Proc Natl Acad Sci U S A,
94,
13163-13168.
|
|
|
|
|
|
|
J.D.Rabinowitz,
K.Tate,
C.Lee,
C.Beeson,
and
H.M.McConnell
(1997).
Specific T cell recognition of kinetic isomers in the binding of peptide to class II major histocompatibility complex.
|
| |
Proc Natl Acad Sci U S A,
94,
8702-8707.
|
|
|
|
|
|
|
J.L.Seibel,
N.Wilson,
H.Kozono,
P.Marrack,
and
J.W.Kappler
(1997).
Influence of the NH2-terminal amino acid of the T cell receptor alpha chain on major histocompatibility complex (MHC) class II + peptide recognition.
|
| |
J Exp Med,
185,
1919-1927.
|
|
|
|
|
|
|
L.Ignatowicz,
W.Rees,
R.Pacholczyk,
H.Ignatowicz,
E.Kushnir,
J.Kappler,
and
P.Marrack
(1997).
T cells can be activated by peptides that are unrelated in sequence to their selecting peptide.
|
| |
Immunity,
7,
179-186.
|
|
|
|
|
|
|
M.A.Batalia,
and
E.J.Collins
(1997).
Peptide binding by class I and class II MHC molecules.
|
| |
Biopolymers,
43,
281-302.
|
|
|
|
|
|
|
P.Cresswell,
and
J.C.Howard
(1997).
Antigen recognition.
|
| |
Curr Opin Immunol,
9,
71-74.
|
|
|
|
|
|
|
P.E.Jensen
(1997).
Peptide binding and antigen presentation by class II histocompatibility glycoproteins.
|
| |
Biopolymers,
43,
303-322.
|
|
|
|
|
|
|
R.T.Carson,
K.M.Vignali,
D.L.Woodland,
and
D.A.Vignali
(1997).
T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage.
|
| |
Immunity,
7,
387-399.
|
|
|
|
|
|
|
V.L.Murthy,
and
L.J.Stern
(1997).
The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide binding.
|
| |
Structure,
5,
1385-1396.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
Y.Itoh,
K.Kajino,
K.Ogasawara,
A.Takahashi,
K.Namba,
I.Negishi,
N.Matsuki,
K.Iwabuchi,
M.Kakinuma,
R.A.Good,
and
K.Onoé
(1997).
Interaction of pigeon cytochrome c-(43-58) peptide analogs with either T cell antigen receptor or I-Ab molecule.
|
| |
Proc Natl Acad Sci U S A,
94,
12047-12052.
|
|
|
|
|
|
|
Z.Reich,
J.D.Altman,
J.J.Boniface,
D.S.Lyons,
H.Kozono,
G.Ogg,
C.Morgan,
and
M.M.Davis
(1997).
Stability of empty and peptide-loaded class II major histocompatibility complex molecules at neutral and endosomal pH: comparison to class I proteins.
|
| |
Proc Natl Acad Sci U S A,
94,
2495-2500.
|
|
|
|
|
|
|
D.H.Fremont,
W.A.Rees,
and
H.Kozono
(1996).
Biophysical studies of T-cell receptors and their ligands.
|
| |
Curr Opin Immunol,
8,
93.
|
|
|
|
|
|
|
L.J.Ausubel,
C.K.Kwan,
A.Sette,
V.Kuchroo,
and
D.A.Hafler
(1996).
Complementary mutations in an antigenic peptide allow for crossreactivity of autoreactive T-cell clones.
|
| |
Proc Natl Acad Sci U S A,
93,
15317-15322.
|
|
|
|
|
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
 |
Links
